Evidence map›Paper›PMID 40892110›Full record

ArticleJournal of gastroenterology2025

Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn's disease in Japan in 2023.

Anna Tsutsui, Yoshitaka Murakami, Yuji Nishiwaki, Keiko Asakura, Satoko Ohfuji, Wakaba Fukushima, Katsuyoshi Matsuoka, Tadakazu Hisamatsu

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Newly Diagnosed Crohn's Disease After SARS-CoV-2 Infection.Case reports in gastrointestinal medicine · 2026
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna TsutsuiDepartment of Medical Statistics, School of Medicine, Toho University, 5-21-16 Omori-Nishi, Ota-Ku, Tokyo, 143-8540, Japan. anna.tsutsui@med.toho-u.ac.jp.ORCID 0000-0001-7696-3717
Yoshitaka MurakamiDepartment of Medical Statistics, School of Medicine, Toho University, 5-21-16 Omori-Nishi, Ota-Ku, Tokyo, 143-8540, Japan.
Yuji NishiwakiDepartment of Environmental and Occupational Health, School of Medicine, Toho University, Tokyo, Japan.
Keiko AsakuraDepartment of Preventive Medicine, School of Medicine, Toho University, Tokyo, Japan.
Satoko OhfujiDepartment of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Wakaba FukushimaDepartment of Public Health, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Katsuyoshi MatsuokaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan.
Tadakazu HisamatsuDepartment of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.

Funding

Ministry of Health, Labour and Welfare 23FC1027
6 · The paper itself

Abstract

backgroundAlmost a decade has passed since the previous nationwide survey on the prevalence of ulcerative colitis (UC) and Crohn's disease (CD) in Japan was conducted in 2015. We conducted a new nationwide hospital-based survey to provide updated estimates of the patient numbers and prevalence rates of UC and CD in Japan in 2023.

methodsStratified random sampling was used to select hospital departments (internal medicine, surgery, pediatrics, and pediatric surgery) that routinely treat UC and CD patients. We sent questionnaires to the sampled departments to request sex-specific information on their patient numbers for UC and CD in 2023. Based on the responses, we estimated the annual patient numbers and prevalence rates of UC and CD throughout Japan. The estimates were compared with those from the previous 2015 survey.

resultsThe overall survey response rate was 50.8% (1,798/3,538 departments). The estimated patient numbers were approximately 316,900 (95% confidence interval: 223,900-409,900) for UC and 95,700 (61,100-130,400) for CD, both of which represent a 1.4-fold increase over the 8-year period since 2015. The annual prevalence rates per 100,000 population were 254.8 (male: 297.5; female: 214.4) for UC and 77.0 (male: 112.9, female: 43.0) for CD. The male-to-female ratios were 1.31 for UC and 2.49 for CD, and the UC-to-CD ratio was 3.31.

conclusionsThe patient numbers and prevalence rates of UC and CD have continued to steadily increase in Japan, suggesting the need for continued monitoring and further investigation to track the disease burden.

Indexed as

Colitis, UlcerativeCrohn DiseaseAdolescentAdultAgedChildFemaleHumansJapanMaleMiddle AgedPrevalenceSurveys and QuestionnairesYoung AdultCrohn’s DiseaseInflammatory Bowel DiseaseJapanPrevalenceUlcerative Colitis

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.